# Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer

> **NCT07593976** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Centre Henri Becquerel** · enrollment: 42 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography

## Key facts

- **NCT ID:** NCT07593976
- **Lead sponsor:** Centre Henri Becquerel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07593976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07593976, "Evaluation of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT for Predicting Pathological Complete Response After Neoadjuvant Chemotherapy in HER2 Positive Early Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07593976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*